, a global provider of clinical laboratory and centralized cardiac services for clinical trials, announced the expansion of testing capabilities at its Toronto laboratory. Additional safety as well as esoteric testing capacity and capabilities will be added to the existing operations.   

"Since the acquisition of this business from MDS Pharma Services last year we have set about improving every aspect of Clearstone's operation and service delivery," said Clearstone CEO Lewis Cameron. "We want Clearstone to be widely recognized as a leader and trusted service provider, committed to long term relationships, operating in an open and transparent way and offering expert, high quality and responsive service to all our clients. This purpose demands renewed investment in people, processes, systems, and infrastructure. The Toronto expansion is one example of our strategic plan and path forward, and we look forward to speaking with clients about these exciting developments.''  

Clearstone CSO Dr. Patrice Hugo added, "The Toronto expansion follows recent investment and expansion at our Beijing site, with particular focus on enhancing our capabilities in flow cytometry and molecular biology. This expansion does result in some duplication of capabilities between our North American laboratories, and as such the laboratory operations at our New Jersey facility will be winding down over a six month period, with any remaining studies to be transitioned to the Toronto laboratory.'' 